Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
Latest Hotspot
4 min read
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
4 September 2023
The FDA has given Mallinckrodt the green light to market Lisdexamfetamine Dimesylate Capsules, a product intended to mitigate Attention-Deficit/Hyperactivity Disorder (ADHD).
Read →
Bifonazole: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Bifonazole: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
4 September 2023
This article summarized the latest R&D progress of Bifonazole, the Mechanism of Action for Bifonazole, and the drug target R&D trends for Bifonazole.
Read →
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
4 September 2023
ACE, or angiotensin-converting enzyme, plays a crucial role in the human body by regulating blood pressure and fluid balance.
Read →
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
Latest Hotspot
4 min read
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
3 September 2023
On September 1, 2023, the NMPA officially approved a new indication for AstraZeneca's blood cancer product, Acalabrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read →
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
Latest Hotspot
3 min read
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
3 September 2023
On September 1, 2023, Mabspace Biosciences registered an international multicenter Phase III clinical trial on the Drug Clinical Trial Registration and Information Publicity Platform.
Read →
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
Latest Hotspot
4 min read
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
3 September 2023
Margetuximab is an Fc-optimized monoclonal antibody acting on HER2, which was introduced by Zai Lab from MacroGenics.
Read →
Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
Latest Hotspot
5 min read
Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
3 September 2023
On August 31, 2023, Sirnaomics announced positive results from Phase 1 clinical trials of its RNAi therapy STP707 for treating various solid tumors.
Read →
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
Latest Hotspot
3 min read
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
3 September 2023
Recently, Neurocrine Biosciences announced new data for the VMAT2 inhibitor drug Ingrezza (valbenazine) capsules, including preliminary results from the Phase III KINECT-HD clinical trial.
Read →
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
2 September 2023
SGLT2 inhibitors use a unique insulin-independent mechanism to lower blood glucose levels, not only effectively and safely reducing glucose, but also providing significant cardio-renal protection.
Read →
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
Latest Hotspot
3 min read
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
2 September 2023
Recently, Bristol Myers Squibb has announced the latest long-term follow-up results of two Phase 3 studies that assessed the treatment efficacy of Camzyos (mavacamten).
Read →
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
Latest Hotspot
3 min read
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
2 September 2023
Recently, Roche announced that its PD-L1 targeted antibody, Tecentriq(atezolizumab), has been approved for marketing in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
Read →
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
Latest Hotspot
4 min read
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
2 September 2023
the combined therapy of KRAS G12D inhibitor MRTX1133 and immune checkpoint inhibitors can cause sustained tumor elimination and significantly improve the survival outcomes in mice.
Read →